Disease relevance of Fanodormo

• The cyclobarbital (CB) half-life was prolonged and the clearance reduced in patients with viral hepatitis, cirrhosis or alcoholic liver damage as compared to data from 17 control subjects [1].

High impact information on Fanodormo

• A method is described for the measurement of blood, serum and/or plasma levels of hexobarbital, phenobarbital, cyclobarbital and phenytoin by ultraviolet reflectance photometry on thin-layer chromatograms [2].
• The RNA-tablets and Phanodorm exhibited similar bioavailability, whereas the average bioavailability of the solution was 78% of that of FNA-tablets; the reason for this unexpected finding is unknown [3].
• The influence of cyclobarbital and diazepam on drug metabolism in vitro and their binding to cytochrome P-450 [4].

Associations of Fanodormo with other chemical compounds

• The pharmacokinetics and relative bioavailability of cyclobarbital calcium have been studied after oral administration of Phanodorm, of tablets according to the Formularium Nederlandse Apothekers (1968; FNA), and an aqueous solution [3].

Analytical, diagnostic and therapeutic context of Fanodormo

• The aggregate-free IgG were passively immunized to C3H mice 1 hr before intraperitoneal injection of cyclobarbital which has a high binding affinity to the antibodies [5].
• Effects of passive immunization with rabbit anti-phenobarbital IgG on cyclobarbital-induced sleeping time and hepatic enzyme activities of C3H mice [5].

References